Transcriptomic analysis of the effect of ifosfamide on MDCK cells cultivated in microfluidic biochips

Genomics

Volumn 100, Issue 1, 2012, Pages 27-34

  Choucha Snouber, Leila ^a   Jacques, Sébastien ^b   Monge, Matthieu ^c   Legallais, Cécile ^a   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b INSTITUT COCHIN   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Drug target; Ifosfamide; Inflammation; Kidney; PDMS microfluidic biochip; Transcriptomic

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; I KAPPA B ALPHA; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN P53; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ARTICLE; BIOCHIP; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL KINETICS; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 1A P21 GENE; DNAJ HOMOLOG SUBFAMILY B MEMBER 4 GENE; DNAJ HOMOLOG SUBFAMILY B MEMBER 9 GENE; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; GENE IDENTIFICATION; HEAT SHOCK PROTEIN 40 GENE; HEAT SHOCK PROTEIN 70 GENE; IKBALPHA GENE; KIDNEY CELL CULTURE; MICROARRAY ANALYSIS; MICROFLUIDICS; MITOCHONDRIAL MEMBRANE; NONHUMAN; ONCOGENE MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THIOREDOXIN REDUCTASE 1 GENE; TP53 GENE; TRANSCRIPTOMICS; TUMOR GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CULTURE TECHNIQUES; DOGS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IFOSFAMIDE; INFLAMMATION; KIDNEY; MICROFLUIDIC ANALYTICAL TECHNIQUES; NEOPLASMS;

EID: 84862773705     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2012.05.001     Document Type: Article

References (42)

1. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B.R., Bader A., Langsch A., Koose T., Burger H.J., Maas J., Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 2003, 35:145-213.
2. Roberts S.A. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001, 31:557-589.
3. Richert L., Abadie C., Bonet A., Heyd B., Mantion G., Alexandre E., Bachellier P., Kingston S., Pattenden C., Illouz S., Dennison A., Hoffmann S., Coecke S. Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. Toxicol. Vitro 2010, 24:335-345.
4. Riley R.J., Grime K. Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. Drug Discov. Today Tech. 2004, 1:365-372.
5. Prot J.M., Aninat C., Griscom L., Razan F., Brochot C., Guguen Guillouzo C., Legallais C., Corlu A., Leclerc E. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol. Bioeng. 2011, 108:1704-1715.
6. Choucha Snouber L., Letourneur F., Chafey P., Broussard C., Monge M., Legallais C., Leclerc E. Analysis of transcriptomic and proteomic profiles demonstrates the improvement of the MDCK cell function in a renal microfluidic biochip. Biotechnol. Prog. 2012, 28:474-484.
7. Prot J.M., Briffaut A.S., Letourneur F., Chafey P., Merlier F., Grandvalet Y., Legallais C., Leclerc E. Integrated proteomic and transcriptomic investigation highlights original insight into paracetamol toxicity in liver biochip. Plos One 2011, 6:21268.
8. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res. 2008, 18:334-342.
9. Elsharkawy A.M., Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007, 46:590-597.
10. Hanly L., Chen N., Rieder M., Koren G. Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. Expert Opin. Drug Saf. 2009, 8:155-168.
11. Schwerdt G., Gordjani N., Benesic A., Freudinger R., Wollny B., Antje K., Gekle M. Chloroacetaldehyde and acrolein induced death of human proximal tubule cells. Pediatr. Nephrol. 2006, 21:60-67.
12. Springate J., Taub M. Ifosfamide toxicity in cultured proximal renal tubule cells. Pediatr. Nephrol. 2007, 22:358-365.
13. Hamberg P., Steeghs N., Loos W., van Biessen D., den Hollander M., Tascilar M., Verweij J., Gelderblom H., Sleijfer S. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. Br. J. Cancer 2010, 102:1699-1706.
14. Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38:355-360.
15. Jiang H., Reinhardt C., Bartkova J., Tommiska J., Blomqvist C., Nevanlinna H., Bartek J., Yaffe M., Hemann M. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009, 23:1895-1909.
16. Wang X., Zhang J., Xu T. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur. J. Pharmacol. 2008, 579:66-73.
17. Biaglow J.E., Miller R.A. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol. Ther. 2005, 4:6-13.
18. Nguyen P., Awwad R., Smart D., Spitz D., Gius David Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 2006, 236:164-174.
19. Jolly C., Morimoto R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 2000, 92:1564-1572.
20. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert. Opin. Biol. Ther. 2002, 2:3-24.
21. Campbell K.S., Mullane K.P., Aksoy I.A., Studbal H., Zalvide J., Pipas J.M., et al. DnaJ/hsp40 chaperone domain of SV40 large T antigen promotes efficient viral DNA replication. Genes Dev. 1997, 11:1098-1110.
22. Kelley W.L., Georgopoulos C. The T/t common exon of simian virus 40, JC, and BK polyomavirus T antigens can functionally replace the Jdomain of the Escherichia coli DnaJ molecular chaperone. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3679-3684.
23. Srinivasan A., McClellan A.J., Vartikar J., Marks I., Cantalupo P., Li Y., et al. The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain. Mol. Cell. Biol. 1997, 17:4761-4773.
24. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 1992, 69:1237-1245.
25. Shangary S., Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 2008, 14:5318-5324.
26. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 1993, 13:4107-4114.
27. Chen W., Sun Z., Wang X.J. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol. Cell 2009, 34:663-673.
28. Wang P., Greiner T.C., Lushnikova T., Eischen C.M. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 2006, 22:3708-3718.
29. Danilkovitch-Miagkova A., Angeloni D., Skeel A., Donley S., Lerman M., Leonard E.J. Integrin mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J. Biol. Chem. 2000, 275:14783-14786.
30. Aplin A.E., Stewart S.A., Assoian R.K., Juliano R.L. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J. Cell Biol. 2001, 153:273-282.
31. Ahmed N., Pansino F., Baker M., Rice G., Quinn M. Association between avB6 integrin expression, elevated p42/44 MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J. Cell. Biochem. 2002, 84:675-686.
32. Barry O.P., Mullan B., Sheehan D., Kazanietz M.G., Shanahan F., Collins J.K., O'Sullivan G.C. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J. Biol. Chem. 2001, 276:15537-15546.
33. Kim S., Hahn J., Min Y., Yoo N., Ko Y., Lee W. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 1999, 93(3893):3899.
34. Towatari M., Lida H., Tanimoto M., Iwata H., Hamaguchi M., Saito H. Constitutive activation of mitogenactivated protein kinase pathway in acute leukemia cells. Leukemia 1997, 11:479-484.
35. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., Okada Y., Kawaichi M., Kohno M., Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995, 55:4182-4187.
36. Benaud C., Dickson R. Regulation of the expression of c-Myc by [U+F062]1 integrins in epithelial cells. Oncogene 2001, 20:759-768.
37. Tsai Y., Teng S., Wu K. Direct regulation of HSP60 expression by c-MYC induces transformation. FEBS Lett. 2008, 582:4083-4088.
38. Kaiser S., Park Y., Franklin J., Halberg R., et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 2007, 8:R131.
39. Bruheim S., Xi Y., Ju J., Fodstad O. Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, vb Cisplatin, and Ifosfamide. Cancer Ther. 2009, 15:7161-7169.
40. Ciarimboli G., Holle S.K., Vollenbröcker B., Hagos Y., Reuter S., Burckhardt G., Bierer S., Herrmann E., Pavenstädt H., Rossi R., Kleta R., Schlatter E. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol. Pharm. 2011, 7(8(1)):270-279.
41. Baudoin R., Griscom L., Prot J.M., Legallais C., Leclerc E. Behavior of HepG2/C3a cell cultures in a microfluidic bioreactor. Biochem. Eng. J. 2011, 53:172-181.
42. Baudoin R., Griscom L., Monge M., Legallais C., Leclerc E. Development of a renal microchip for in vitro distal tubule models. Biotechnol. Prog. 2007, 23:1245-1253.